● Recruiting

To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Condition: Basal Cell Carcinoma · Sponsor: Stamford Pharmaceuticals, Inc.

PhasePhase 2

Planned participants80

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an add-on to hedgehog pathway inhibitor therapy. Researchers will compare the objective response rate for treated Basal cell carcinoma tumors between 3 treatment Arms. * Arm 1 participants will receive daily hedgehog pathway inhibitor, and 3 cycles of SP-002 treatment. * Arm 2 participants will receive daily hedgehog pathway inhibitor, and 1 cycle of SP-002 treatment. * Arm 3 participants will receive daily hedgehog pathway inhibitor only.

This description comes directly from the study's public registry record.

Talk to the study team

Stamford Pharmaceuticals · 5126944241 · clinicaltrials@stamfordpharmaceuticals.com

Always discuss trial participation with your own doctor first.

Locations (10)

Research Site	Phoenix, Arizona, United States	Recruiting
Research Site	Boca Raton, Florida, United States	Recruiting
Research Site	Coral Springs, Florida, United States	Recruiting
Research Site	Cutler Bay, Florida, United States	Recruiting
Research Site	Rockville, Maryland, United States	Recruiting
Research Site	Lee's Summit, Missouri, United States	Recruiting
Research Site	Rochester, New York, United States	Recruiting
Research Site	Cedar Park, Texas, United States	Recruiting
Research Site	Humble, Texas, United States	Recruiting
Research Site	Longview, Texas, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06344052